The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Can MRD guide treatment of post-transplant dara-KRd consolidation?

Dec 13, 2019

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Luciano J. Costa, University of Alabama at Birmingham, Birmingham, US, answers the question: Can the minimal residual disease (MRD) status guide combination treatment of daratumumab (dara), carfilzomib, lenalidomide and dexamethasone (KRd) post-transplant consolidation?

In this video Dr Costa discusses the quadruplet of dara-KRd as induction followed by transplant and dara-KRd consolidation, and the use of MRD assessment as an endpoint as well as a decision-making tool.

Can MRD guide treatment of post-transplant dara-KRd consolidation?